← Leaderboards
Elif Arioglu Oral
University Of Michigan At Ann Arbor
$3,078,263
Attributed
$5,834,966
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,834,966 · 9
By mechanism
R01$4,864,073 · 3
R21$415,334 · 1
R03$299,759 · 1
R56$234,000 · 1
M01$21,800 · 3
Top collaborators
- Ormond A Macdougald6 shared
- Hari S Conjeevaram5 shared
- Alan R. Saltiel2 shared
- Simeon I Taylor1 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Graham F. Brady$1,072,500
- Ormond A Macdougald$22,943,906
- Brian Francis Zamarron$90,176
- Paulette B. Goforth$2,926,039
- Jessica Nanda Maung$97,520
Research focus
Fatty Acid Glycerol EstersInsulin ResistanceLiverMetabolicLeptinAdipocytesFatty LiverFastingLipodystrophyInsulinObesityInflammationGene ExpressionHormonesBrown FatPathway InteractionsAdipose TissueGlucose MetabolismLeptin DeficiencyDepositionGenesDoseAffectLink
Grant awards (20)
Tirzepatide for treatment of familial partial lipodystrophy$793,098
R01 · FY2025 · DK · contact PI
Mechanisms of adipocyte loss in laminopathy-induced lipodystrophy in mice and humans$658,801
R01 · FY2025 · DK
Mechanisms of adipocyte loss in laminopathy-induced lipodystrophy in mice and humans$669,659
R01 · FY2024 · DK
Mechanisms of adipocyte loss in laminopathy-induced lipodystrophy in mice and humans$234,000
R56 · FY2023 · DK
Mechanisms of adipocyte loss in laminopathy-induced lipodystrophy in mice and humans$351,000
R01 · FY2022 · DK
Mechanisms of adipocyte loss in laminopathy-induced lipodystrophy in mice and humans$351,000
R01 · FY2021 · DK
Mechanisms of adipocyte loss in laminopathy-induced lipodystrophy in mice and humans$312,000
R01 · FY2020 · DK
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)$338,213
R01 · FY2015 · DK · contact PI
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)$338,213
R01 · FY2014 · DK · contact PI
Probing the relevance of the "counter-inflammatory" noncanonical IkB kinases in r$191,587
R21 · FY2014 · DK · contact PI
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)$326,376
R01 · FY2013 · DK · contact PI
Probing the relevance of the "counter-inflammatory" noncanonical IkB kinases in r$223,747
R21 · FY2013 · DK · contact PI
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)$338,213
R01 · FY2012 · DK · contact PI
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)$387,500
R01 · FY2011 · DK · contact PI
RECOMBINANT LEPTIN THERAPY FOR TREATMENT OF NASH$147,592
R03 · FY2007 · DK · contact PI
NONALCOHOLIC STEATOHEPATITIS (NASH): IS LEPTIN AN ETIOLOGICAL FACTOR (PHASE2)$1,582
M01 · FY2007 · RR · contact PI
NONALCOHOLIC STEATOHEPATITIS (NASH): IS LEPTIN AN ETIOLOGICAL FACTOR (PHASE 1)$678
M01 · FY2007 · RR · contact PI
RECOMBINANT LEPTIN THERAPY FOR TREATMENT OF NASH$152,167
R03 · FY2006 · DK · contact PI
NONALCOHOLIC STEATOHEPATITIS (NASH): IS LEPTIN AN ETIOLOGICAL FACTOR (PHASE 1)$2,043
M01 · FY2006 · RR · contact PI
NONALCOHOLIC STEATOHEPATITIS (NASH): IS LEPTIN AN ETIOLOGICAL FACTOR (PHASE 1)$17,497
M01 · FY2005 · RR